Posts Tagged ‘breakthrough’
Walkerton Tragedy: 10 years of water contamination research leads to breakthrough
Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome. The sheer scale of infection and the recording of the health of Walkerton’s citizens gave a team of researchers a unique opportunity to study the origin of this disorder.
Breakthrough Cancer Pain: First Results From Major European Patient Survey
The first results of the first European survey of cancer patients’ experience of breakthrough pain were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC). Previous surveys have looked at the overall management of pain in cancer patients but this is the first international study to look in detail at Breakthrough Cancer Pain (BTCP) from a patient perspective.
Instanyl(R) (intranasal Fentanyl Spray) Sets New Standard In Management Of Breakthrough Cancer Pain
New data presented further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
Instanyl Sets New Standard In Management Of Breakthrough Cancer Pain
New data presented today, 11-Sep-2009, further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
BUPA Launches Breakthrough Treatment For Back And Knee Pain
New research reveals around 22 million people suffered back pain in the last year – just under half of all UK adults (45 percent)[1]. More than one in four UK adults – nearly 13 million people – suffered from knee pain in the last year. Over 80 percent of the people with back or knee pain still suffer some pain after undergoing treatment recommended by a healthcare professional. Bupa is making APOS Treatment for knee and lower back pain available in the UK for the first time.
Pharmacy 102: Breakthrough Medicines
 |
Almost every American takes a drug every day; many take three or more. Where have those breakthrough medicines come from and how do they contribute to longevity and quality of life? Join William Soller of UCSF's School of Pharmacy and learn how breakthrough medicines are discovered. Series: "UCSF Mini Medical School for the Public" [9/2007] [Health and Medicine] [Show ID: 13010]
|
From:uctelevision
Views:1004
 1ratings
|
| Time:01:15:47 | More inEducation |
Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain
Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, announces new positive headline phase III results for NasalFent(R), the Company’s innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain.
Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain
Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, announces new positive headline phase III results for NasalFent(R), the Company’s innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.
New Therapy Options For Breakthrough Pain – European Association For Palliative Care
A series of therapeutic innovations that will be introduced at the EAPC Congress should further improve medical provisioning of palliative patients in matters of symptom control. A serious problem involving cancer patients is so-called “breakthrough pain”: this is an instantaneous intensive sharp pain, additional to “all-over” dull pain, that usually lasts only a half-hour to one hour and reaches its highest intensity some minutes after the outbreak.
AcelRx Announces Initiation Of Phase 2 Cancer Breakthrough Pain Program
AcelRx Pharmaceuticals, Inc. announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab(TM) product candidate for cancer breakthrough pain control. The primary objective of this multicenter, randomized, placebo-controlled, crossover study is assessment of safety, tolerability and efficacy of ARX-02 relative to placebo in cancer patients experiencing episodic breakthrough pain.
Rx Drug Compare
Translator
By N2H